An Anti-PD-1-GITR Ligand Bispecific Enhances Antitumor Immunity.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
02 05 2022
02 05 2022
Historique:
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
4
5
2022
Statut:
ppublish
Résumé
A PD-1-directed, multimeric GITR agonist enhances immune cell activation to inhibit tumor growth.
Identifiants
pubmed: 35491629
pii: 694537
doi: 10.1158/2159-8290.CD-RW2022-049
doi:
Substances chimiques
Glucocorticoid-Induced TNFR-Related Protein
0
Ligands
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
OF10Informations de copyright
©2022 American Association for Cancer Research.